登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，2月3日，A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2021-02-25

  • A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
    Qingrui Huang, Kai Ji, Siyu Tian, Fengze Wang, Baoying Huang, Zhou Tong, Shuguang Tan, Junfeng Hao, Qihui Wang, Wenjie Tan, George F. Gao & Jinghua Yan
    Nature Communications volume 12, Article number: 776 (2021)

    Abstract
    The rapid expansion of the COVID-19 pandemic has made the development of a SARS-CoV-2 vaccine a global health and economic priority. Taking advantage of versatility and rapid development, three SARS-CoV-2 mRNA vaccine candidates have entered clinical trials with a two-dose immunization regimen. However, the waning antibody response in convalescent patients after SARS-CoV-2 infection and the emergence of human re-infection have raised widespread concerns about a possible short duration of SARS-CoV-2 vaccine protection. Here, we developed a nucleoside-modified mRNA vaccine in lipid-encapsulated form that encoded the SARS-CoV-2 RBD, termed as mRNA-RBD. A single immunization of mRNA-RBD elicited both robust neutralizing antibody and cellular responses, and conferred a near-complete protection against wild SARS-CoV-2 infection in the lungs of hACE2 transgenic mice. Noticeably, the high levels of neutralizing antibodies in BALB/c mice induced by mRNA-RBD vaccination were maintained for at least 6.5 months and conferred a long-term notable protection for hACE2 transgenic mice against SARS-CoV-2 infection in a sera transfer study. These data demonstrated that a single dose of mRNA-RBD provided long-term protection against SARS-CoV-2 challenge.

  • 原文来源：https://www.nature.com/articles/s41467-021-21037-2
199浏览量
原文链接
相关报告

  • 《Prnewswire，2月14日，Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：YUTING
    • 发布时间：2022-02-23
    • TAIZHOU, China, Feb. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (Recbio), a China-based company focused on the development of innovative vaccines for major diseases, announced preclinical data of its subsidiary Wuhan Recogen Biotechnology Co., Ltd. (Recogen) on lyophilized mRNA vaccine. The lyophilized mRNA-LNP nanoparticle vaccine is delivered by an LNP delivery system and achieved stability at 4℃ and 25℃ based on a self-developed lyophilization technology. The vaccine can be stored and transported in conventional cold chain conditions, greatly improving the accessibility of mRNA vaccine. The results have been on the preprint server bioRxiv According to this paper, Recogen developed the lyophilized mRNA-LNP nanoparticle vaccine targeting wild-type, Delta and Omicron SARS-CoV-2 variant, and the data showed that the lyophilized process did not affect the key physicochemical parameters, biological activity and immunogenicity of the vaccine. Notably, the Delta-specific mRNA vaccine can induce a high-level neutralization response in mice against both the wild-type and the current global pandemic strain Omicron. A virus challenge study of hACE2 transgenic mice shows the lyophilized mRNA-Delta vaccine is highly immunogenic and can fully protect the challenged mice from SARS-COV-2 infection and clear the virus. Vaccines have become the world's most cost-effective tool to respond to the COVID-19. As of now, more than 10 billion doses of COVID-19 vaccine have been administered globally. However, only 10% of people in low-income countries have received at least one dose of vaccine. Therefore, it is particularly important to develop an mRNA vaccine that can be transported in conventional cold-chain and be stored at 2℃~8℃, or at room temperature stably for broad application. Recogen successfully achieved the lyophilization of mRNA-LNP vaccine. This lyophilization platform could significantly improve the accessibility of mRNA vaccines or therapeutics, particularly in remote regions. The paper links: https://www.biorxiv.org/content/10.1101/2022.02.10.479867v2.full.pdf
    116浏览量
    原文链接

  • 《Nature，5月7日，The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-08
    • The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice Linlin Bao, Wei Deng, […]Chuan Qin Nature (2020) Abstract Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) caused the corona virus disease 2019 (COVID-19) cases in China and has become a public health emergency of international concern1. Because angiotensin-converting enzyme 2 (ACE2) is the cell entry receptor of SARS-CoV5, we used transgenic mice bearing human ACE2 and infected with SARS-CoV-2 to study the pathogenicity of the virus. Weight loss and virus replication in lung were observed in hACE2 mice infected with SARS-CoV-2. The typical histopathology was interstitial pneumonia with infiltration of significant macrophages and lymphocytes into the alveolar interstitium, and accumulation of macrophages in alveolar cavities. Viral antigens were observed in the bronchial epithelial cells, macrophages and alveolar epithelia. The phenomenon was not found in wild-type mice with SARS-CoV-2 infection. Notably, we have confirmed the pathogenicity of SARS-CoV-2 in hACE2 mice. The mouse model with SARS-CoV-2 infection will be valuable for evaluating antiviral therapeutics and vaccines as well as understanding the pathogenesis of COVID-19.
    254浏览量
    原文链接